Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
NCT ID: NCT01467661
Last Updated: 2021-06-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
41 participants
INTERVENTIONAL
2010-10-27
2015-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia
NCT01214915
Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia
NCT01230775
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
NCT00202644
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
NCT03232177
Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
NCT05369208
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SPD422 (anagrelide hydrochloride)
SPD422 (anagrelide hydrochloride)
Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SPD422 (anagrelide hydrochloride)
Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akita University Hospital
Akita, Akita, Japan
Tokyo Metropolitan Cancer and Infectious diseases Center Kom
Honkomagome 3-18-22, Bunkyo-ku, Japan
Nippon Medical School Hospital
Sendagi 1-1-5, Bunkyo-ku, Japan
Chiba University Hospital
Chuo-ku Inohana 1-8-1, Chiba-shi, Japan
Hokkaido University Hospital
Sapporo, Hokkaidō Prefecture, Japan
Tokai University Hospital
Isehara-shi, Kanagawa, Japan
Gunma University Hospital
Showa-machi 3-39-15, Maebashi-shi, Japan
NHO Tokyo Medical Center
Higashigaoka 2-5-1, Meguro-ku, Japan
Mie University Hospital
Tsu, Mie-ken, Japan
University of Miyazaki Hospital
Miyazaki, Miyazaki, Japan
Niigata Cancer Centre
Niigata, Niigata, Japan
Okayama University Hospital
Okayama, Okayama-ken, Japan
Osaka City University Hospital
Osaka, Osaka, Japan
Osaka University Hospital
Suita-shi, Osaka, Japan
Juntendo University Shizuoka Hospital
Izunokuni-shi, Shizuoka, Japan
Keio University Hospital
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kanakura Y, Shirasugi Y, Yamaguchi H, Koike M, Chou T, Okamoto S, Achenbach H, Wu J, Nakaseko C. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia. Int J Hematol. 2018 Nov;108(5):491-498. doi: 10.1007/s12185-018-2510-7. Epub 2018 Aug 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPD422-309
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.